Mankind Pharma543904Pharmaceuticals
Mankind Pharma shares jumped 9% after Q2 earnings beat driven by strong domestic pharma growth and margin expansion
By ScoutQuest · · 1 min read
- Stock move today
- 9 percent
- Gross margin improvement
- 90 basis points
- Gross margin level
- 72 percent
- Chronic share growth
- 37 percent
- Target chronic mix
- 50 percent
Heard on business television between 14:36:20 - 14:39:20 IST.
- Stock traded at day's high, up 8-9% on strong Q2 earnings and management commentary.
- Gross margin improved 90 basis points to almost 72%, aided by better product mix and operating leverage.
- Chronic therapy share rose almost 37%, with company targeting 50% chronic mix over next four to five years; strong traction in cardiac, diabetes and respiratory.
- BSV acquisition benefits coming through; management expects IPM growth of 1.2 times market growth.
- Jefferies maintained rating but cut target price citing weak consumer health growth, while raising FY27-29 EBITDA estimate by 3%; Kotak maintained buy with target price of 3000 rupees, baking in 20% sales CAGR for BSV over FY26-29.
Watch at source
behind live
- 1Open on YouTube
- 2Drag the seek bar left
- 3Watch this moment
Also from Mankind Pharma
Mankind Pharma investor deck: FY26 revenue crosses ₹14.2k Cr, chronic share targeted at ~50% by FY30, 70% stake in Belgian CAR-T firm ACTx
27 Oct 2026
Mankind Pharma's strong Q2 results won brokerage support, with Jefferies and Kotak retaining buy ratings
27 Oct 2026
Mankind Pharma stock surged nearly 10% after a strong conference call following its results announced during market hours
27 Oct 2026
Source: Live TV News Channel · 27 Oct 2026
Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.